ArticleCirculation research2017
Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial Infarction in Mice.
Open access · bronzeAbstract read
In one paragraph
Article in Circulation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 201 citations in OpenAlex.
- Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation.Science advances · 2026Article
- Advances in the clinical application of mesenchymal stem cells for neurological disorders.Stem cell research & therapy · 2026Review
- Off‑the‑shelf, engineered non-living stem cell strategy for advancing cellular therapies.Nature biomedical engineering · 2026Article
- Intrapericardially injected hydrogel loaded with stromal cell secretome microparticles improves post-infarction myocardial repair in pigs.European heart journal · 2026Article
- Avenues for optimization of cardiac therapeutics by minimally invasive delivery.Acta biomaterialia · 2026Review
- Stromal-platelet membrane-inspired nanoparticles (SPIN) for targeted heart repair.Bioactive materials · 2025Article
- Cardiomyocyte pyroptosis inhibited by dental pulp-derived mesenchymal stem cells via the miR-19a-3p/IRF-8/MAPK pathway in ischemia-reperfusion.Chinese medical journal · 2025Article
- Targeted delivery of engineered adipose-derived stem cell secretome to promote cardiac repair after myocardial infarction.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- MiR-21-5p-enriched exosomes from hiPSC-derived cardiomyocytes exhibit superior cardiac repair efficacy compared to hiPSC-derived exosomes in a murine MI model.World journal of stem cells · 2025Article
- Decoding the exosomal secretome: stem cell-elicted microenvironmental reprogramming for anterior cruciate ligament regenerative medicine.Frontiers in bioengineering and biotechnology · 2025Review
- Application of Biomimetic Cell Membrane-Coated Nanocarriers in Cardiovascular Diseases.International journal of nanomedicine · 2025Review
- Article
- Effect of nHA/CS/PLGA delivering adipose stem cell-derived exosomes and bone marrow stem cells on bone healing-in vitro and in vivo studies.Scientific reports · 2024Article
- Review
- Classes of Stem Cells: From Biology to Engineering.Regenerative engineering and translational medicine · 2024Article
- Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment.Biomolecules · 2024Review
- Therapeutic potential of mesenchymal stem cells from human iPSC-derived teratomas for osteochondral defect regeneration.Bioengineering & translational medicine · 2024Article
- Targeted HBiomaterials research · 2024Article
- Frontiers of stem cell engineering for nanotechnology-mediated drug delivery systems.ADMET & DMPK · 2024Review
- Preparation and biomedical applications of artificial cells.Materials today. Bio · 2023Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 3 institutions in 3 countries.
Lan LuoFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Junnan TangFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Kodai NishiFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Chen YanFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Phuong-Uyen DinhFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Jhon CoresFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Takashi KudoFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Jinying ZhangFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Tao-Sheng LiFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.).
Ke ChengFrom the Department of Stem Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Japan (L.L., C.Y., T.-S.L.); Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Japan (K.N., T.K.); Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China (J.T., J.Z.); Department of Molecular Biomedical Sciences and Comparative Medicine Institute (J.T., P.-U.D., J.C., K.C.) and Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh (J.T., P.-U.D., J.C., K.C.); and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (K.C.). ke_cheng@ncsu.edu litaoshe@nagasaki-u.ac.jp.
First Affiliated Hospital of Zhengzhou University · CNUniversity of North Carolina at Chapel Hill · USNagasaki University · JP
Funding
Targeted Nanoparticles for Stem Cell Redirecting and Regenerative MedicineR01HL123920 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2015 to 2023
$4.8MEnhancing vascular delivery of stem cells and microparticlesR01HL137093 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2017 to 2020
$1.5MNHLBI NIH HHS R01 HL123920NHLBI NIH HHS R01 HL137093
Abstract
rationaleStem cell therapy faces several challenges. It is difficult to grow, preserve, and transport stem cells before they are administered to the patient. Synthetic analogs for stem cells represent a new approach to overcome these hurdles and hold the potential to revolutionize regenerative medicine.
objectiveWe aim to fabricate synthetic analogs of stem cells and test their therapeutic potential for treatment of acute myocardial infarction in mice. METHODS AND
resultsWe packaged secreted factors from human bone marrow-derived mesenchymal stem cells (MSC) into poly(lactic-co-glycolic acid) microparticles and then coated them with MSC membranes. We named these therapeutic particles synthetic MSC (or synMSC). synMSC exhibited a factor release profile and surface antigens similar to those of genuine MSC. synMSC promoted cardiomyocyte functions and displayed cryopreservation and lyophilization stability in vitro and in vivo. In a mouse model of acute myocardial infarction, direct injection of synMSC promoted angiogenesis and mitigated left ventricle remodeling.
conclusionsWe successfully fabricated a synMSC therapeutic particle and demonstrated its regenerative potential in mice with acute myocardial infarction. The synMSC strategy may provide novel insight into tissue engineering for treating multiple diseases.
Indexed as
AnimalsCells, CulturedHumansLactic AcidMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMice, Inbred C57BLMyocardial InfarctionPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerPositron-Emission TomographyTreatment OutcomeLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymerartificial cellsmesenchymal stem cellsmyocardial infarctionregenerationstem cellstissue engineering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.